

# FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response. . . . 0.5

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person* Bethwaite Gordon		2. Date of Event Requiring Statement (Month/Day/Year)  12/27/2016	3. Issuer Name <b>and</b> Ticker or Trading Symbol Guardion Health Sciences, Inc. <span style="float: right;">none</span>	
(Last)	(First)		(Middle)	4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  <input type="checkbox"/> Director <span style="margin-left: 100px;"><input type="checkbox"/> 10% Owner</span> <input checked="" type="checkbox"/> Officer (give title below) <span style="margin-left: 100px;"><input type="checkbox"/> Other (specify below)</span> Vice President Sales/Marketing
15150 AVENUE OF SCIENCE, SUITE 200  SAN DIEGO CA 92128				
(City)	(State)	(Zip)	<b>Table I -- Non-Derivative Securities Beneficially Owned</b>	
1. Title of Security (Instr. 4)  Common Stock				
			4. Nature of Indirect Beneficial Ownership (Instr. 5)	

5. If Amendment, Date  
Original Filed (Month/Day/Year)

6. Individual or Joint/Group  
Filing (Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.  
\* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

Table II -- Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Securities (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

Explanation of Responses:

See attached "FOOTNOTES" page.

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations.  
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,  
See Instruction 6 for procedure.

/s/ Vincent J. Roth, attorney-in-fact for  
Gordon Bethwaite

\*\* Signature of Reporting Person

12/27/2016

Date

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

- 1 This Restricted Stock Grant was 50% vested on June 30, 2016, with 25% scheduled to vest on December 31, 2016 and 25% scheduled to vest on June 30, 2017.